Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Iacobelli

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|August 29, 2025
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMTJuan Carlos Hernández-Boluda, Vipul Sheth, Simona Iacobelli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
Bone Marrow Transplantation|December 2, 2021
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMTTomasz Czerw, Simona Iacobelli, Vittoria Malpassuti, et al.
Bone Marrow Transplantation|July 30, 2025
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMTSimona Iacobelli, Stefan Schönland, Linda Koster, et al.
Bone Marrow Transplantation|June 14, 2023
Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Bone Marrow Transplantation|March 30, 2022
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWPFrancesco Onida, Giulia Sbianchi, Aleksandar Radujkovic, et al.
Bone Marrow Transplantation|May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow TransplantationJan Styczynski, Gloria Tridello, Lidia Gil, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|August 29, 2025
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMTJuan Carlos Hernández-Boluda, Vipul Sheth, Simona Iacobelli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
Bone Marrow Transplantation|December 2, 2021
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMTTomasz Czerw, Simona Iacobelli, Vittoria Malpassuti, et al.
Bone Marrow Transplantation|July 30, 2025
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMTSimona Iacobelli, Stefan Schönland, Linda Koster, et al.
Bone Marrow Transplantation|June 14, 2023
Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Bone Marrow Transplantation|March 30, 2022
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWPFrancesco Onida, Giulia Sbianchi, Aleksandar Radujkovic, et al.
Bone Marrow Transplantation|May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow TransplantationJan Styczynski, Gloria Tridello, Lidia Gil, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
Pageof 9